ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0316

High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis

Siba Raychaudhuri1, Yasser Abdelhafez2, Soumajyoti Sarkar3, Smriti Raychaudhuri4 and Abhijit Chaudhari2, 1Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 2University of California, Davis, Sacramento, CA, 3University of California, Davis, Davis, 4VA Sacramento Medical Center, Davis, CA

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Imaging, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis (PsA) outcome measures (DAPSA, Leeds Enthesitis Index, etc). The objective of our study is to determine the association of in vivo PET/CT measures, and use these data to create a catalog of systemic PsA musculoskeletal pathologies and compare with that of RA and OA.

Methods: Patients with RA, PsA or OA were enrolled in IRB-approved studies. All subjects underwent a single-timepoint PET/CT scan on either the total body uEXPLORER scanner or the UC Davis extremity PET/CT scanner for 20 minutes starting at either 40 or 70 minutes after IV injection of 18F-FDG (~1/4th of the conventional dose). Qualitative findings and different patterns for the three conditions were evaluated. We quantified the degree of inflammation in the extremities and whole-body, respectively and determine pathologic predilection for anatomical domains of bones/ligaments of hands in PsA, RA and OA.

Results: Here we will share data from recruited 20 patients, all males, with RA (n=7; median age: 67 years), PsA (n=10; median age: 68 years), OA (n=3; median age: 60 years). The RA patients had symmetric joint involvement, most commonly in the hands/knees. The following sites were involved: radio-and/or ulno-carpal compartments (n=5), MCP (n=4), PIP (n=5) joints. Joints of the feet appeared to be less frequently affected. All PsA patients demonstrated multiple sites of enthesitis (n=10/10), affected the tendons of the hands/fingers and seemed more active on the extensor side (n=5). Increased nail matrix/fingernail FDG uptake was observed to be a distinct feature (n=8/10). Several large joints showed positive findings in all patients. Less frequent features included sausage finger (n=2), plantar fasciitis (n=3); sacroiliac joint (n=2). Involvement of the interspinous ligament (n=2) and facet joints (n=2) was also noted. Patients with OA showed unilateral enhanced FDG uptake at least one big joint (shoulder, n=3; elbow, n=1; knee, n=2), and small joints of the hand/feet (1st CMC/1st MTP).

Conclusion:

  1. Asymmetric synovitis of small joints of hands/feet, enthesitis, nail matrix inflammation, dactylitis and spondylitis stands out to be pathologic features for PsA.
  2. There appeared to be an overall concurrence between degree of inflammation by imaging and clinical outcome measures of PsA such as DAPSA and Leeds Enthesitis Index.
  3. We expect at the completion of this study these clinico-radiologic domains will provide for unique quantitative diagnostic imaging biomarkers for PsA and a single PET imaging scan will be able to differentiate from other inflammatory/non-inflammatory conditions like RA and OA.

Fig 1: Enthesitis on PET/CT in PsA: Extensor digitorum tendon uptake at the central slip, showing enthesitis; (A) Maximum-intensity projection through the PET scan of the right hand of a participant with PsA showing entheseal uptake at the third PIP joint; axial (B) and sagittal (D) sections through the CT scan of the third PIP joint (grayscale); and axial (C) and sagittal (E) section from the overlay of PET (color) on CT (grayscale).

Fig 2: Nail matrix involvement in PsA: (A) Maximum-intensity projection through the PET scan of the left hand of a participant with PsA showing nail involvement; sagittal (B) CT and (C) PET/CT (PET in color, CT in grayscale) of the second digit showing nail bed inflammation. (D) shows nail bed involvement in a participant with PsA from our previous study for comparison.


Disclosure: S. Raychaudhuri, AbbVie, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sun Pharmaceutical Industries, Inc., 2, Amgen, 5, Eli Lilly, 5; Y. Abdelhafez, None; S. Sarkar, None; S. Raychaudhuri, None; A. Chaudhari, None.

To cite this abstract in AMA style:

Raychaudhuri S, Abdelhafez Y, Sarkar S, Raychaudhuri S, Chaudhari A. High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/high-sensitivity-18f-fdg-pet-ct-a-diagnostic-tool-for-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-sensitivity-18f-fdg-pet-ct-a-diagnostic-tool-for-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology